Diapositive 1

The Recognition of exclusive right in Biotechnology and
comparative studies on solutions in China, Europe and France
CDA & UMR 1027
Supervisors : Jacques LARRIEU & AnneMarie DUGUET
Mou Li
Law PhD student
Doctoral school:
Start date: 2012
Funding:
Previous education:
Doctoral school of law and political sciences
CSC & University of Toulouse
2011-2012: Master2 in Intellectual Property law, University of Toulouse I
2010-2011: Master 1 in International & European Law, University of Toulouse I
2009-2010: International Management (MBA), Lyon University
2005-2009: B.A in Law, Beijing University
Background
There is a trend of worldwide harmonization of patent law, due to the harmonization lead by TRIPS of WTO and WIPO that
examination is similar globally. However, the standards among states can differ. The biotechnology itself is more interdisciplinary in
practice as it is not only in the concern of the national strategy but also for the profit of entire human race.
Exclusive rights are derived from notion of possess. The balance of IPRs and advancing technology seems to be challenged in ever
glooming biotechnology industry. Research questions
What is an exclusive right in technology or science oriented industry and in what circumstance it can be protected? Results
While protecting exclusive rights in biotechnology and pharmaceutical industry a constrain to public health or a promote to
advancing entire social benefit? Perspectives
Can there be a unified global law on biotechnology? Perspectives
Origin of exclusive rights: the first patent law –
France
Protection under patent framework: in common or in differ
Fundamental requirements: a trend in patent regime to have a worldwide harmonized
protection, but only in theory.
Recipes of Sybaris in 1474
Invention patents came into sights in 1791 in France
the law on 5th July 1844 in France
ever since 1780 the question on exclusive privilege over
certain rights, nowadays that the exclusive rights are
Scope of exclusive rights
mostly seen in the copyright, but the practice of patent
and its importance is still the main reason for protection
All field of
technology
New
Inventive steps
Industry
applicable
Y
Y
Y
Y
TRIPS (Art. 27.1)
Art. 52.1
Art. 54
Art. 56
Art. 57
European Patent
Convention
---
Y
Y
Y
Biotechnology
directive 98/44/EC
(Art. 3)
L. 611-10
Art. L.611-11
Art. L.611-14
Art. L.611-15
French intellectual
property code
N
Y
Y
Y
Chinese patent law
(Art 22)
What is biotechnology and what is the proper
term?
Karal Ereky
Karal Ereky 1919 first combined the two
terms together as Biological and
technology
Modern science
Discovery of DNA structure in 1953
OECD, Convention on biological diversity
Unitary definition
Industry application Biotechnology invention in European
patent convention rule 26(2)
Bio similar
EMA
Protection under patent framework: in common or in differ
Longer
Bio similar or bio-generics, and its pioneer drugs
Contents of exclusivity
Patents
Trade secrets
Data protection
These are the main forces to be considered in not
only biotechnology but any scientific oriented industries.
Three questions shall be taken into concern :
1, Why they are many terms for biopharmaceutical products and the
rationale behind it?
2, What is the exclusive rights that are so important to the big enterprises
that they are not really willing to invest more on research in biological
medication?
3, Second generation patent and secondary patent for the blockbuster
References
1. Commission on Intellectual Property Rights, Innovation and Public Health, Public Health, Innovation and Intellectual Property Rights, World
Health Organization
2. International law and Institutions, International law on biotechnology, Der-Chin Horng
3. Des brevets et des marques, A. Beltran, S. Chauveau, and G. Galvez, Fayard, 2001
4. La République des inventeurs, G. Galvez-Behar,PUR, 2008
5. Jean-Marc Mousseron, Traié des brevets, Libraires techniques, 1984
6. Jean-Marc Mousseron, Les brevet d’invention, Presses universitaires de France, 1973
7. Jean-Christophe Galloux, Peter Beyer, Ahmed Abdel Latif, Jacques de Werra, La propriété intellectuelle dans l’industrie pharmaceutique,
Schulthess, 2012
8. Albert Chavanne, Jean-jacques Burt, Jacques Azéma, Jean-Christophe Galloux, Droit de la propriété industrielle, Dalloz, 2012
9. Jacques Larrieu, Le droit des affaires, l’Hermès, 1996